文献速递心脑血管急症重症综合管理与镇静镇痛

心脏骤停幸存者达到目标体温的时间重要吗:系统评价与Meta分析

Does Time to Achieve a Targeted Body Temperature Matter for Survivors of Cardiac Arrest? A Systematic Review and Meta-Analysis.
PubMed 文献 · Crit Care Med · 2025-11-11
一句话结论早期低温控制未改善心脏骤停幸存者神经结局或生存率,鼻蒸发冷却用于可除颤心律者可能获益,但未达统计学显著。

该系统评价与Meta分析纳入11项前瞻性随机对照试验,比较ROSC后30分钟内启动早期低温控制与晚期低温控制对昏迷成人心脏骤停患者的影响。早期冷却未改善神经结局(RR 1.01,95%CI 0.94-1.14)或生存率(RR 1.01,95%CI 0.92-1.11)。复苏期间启动鼻蒸发冷却对可除颤心律患者可能获益(RR 1.40,95%CI 1.00-1.96),而CPR期间给予冷液体与再停搏风险升高相关。10项研究在院前启动冷却,其中9项入院时未达到目标温度(32-34°C),达到目标温度的中位时间范围为38至360分钟。

要点

  • 早期低温控制(ROSC后30分钟内启动)未改善神经结局(RR 1.01,95%CI 0.94-1.14)或生存率(RR 1.01,95%CI 0.92-1.11)。
  • 复苏期间启动鼻蒸发冷却对可除颤心律患者可能获益(RR 1.40,95%CI 1.00-1.96)。
  • CPR期间给予冷液体与再停搏风险升高相关。
  • 10项院前启动冷却的研究中9项入院时未达到目标温度(32-34°C),达到目标温度中位时间38至360分钟。
  • 作者认为达到目标温度的延迟可能是低温控制失败的原因,未来研究应评估30分钟内达到目标温度是否快速改善结局。

适用人群与场景

  • 昏迷的成人心脏骤停患者,纳入前瞻性随机对照试验。

诊断标准与关键阈值

  • 早期冷却定义为ROSC后30分钟内启动低温控制。
  • 目标温度范围为32-34°C。

研究设计与关键结果

  • 系统评价与Meta分析,共检索7269条文献,最终纳入11项前瞻性随机对照试验。
  • 早期冷却未改善神经结局(RR 1.01,95%CI 0.94-1.14),也未改善生存率(RR 1.01,95%CI 0.92-1.11)。
  • 复苏期间启动鼻蒸发冷却对可除颤心律患者可能获益(RR 1.40,95%CI 1.00-1.96)。
  • CPR期间给予冷液体与再停搏风险升高相关。
  • 10项研究在院前启动冷却,其中9项入院时未达到目标温度(32-34°C)。
  • 达到目标温度的中位时间范围为38至360分钟。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入前瞻性随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 早期低温控制(ROSC后30分钟内启动)未显示神经结局或生存获益。
  • 作者认为鼻蒸发冷却在复苏期间启动可能对可除颤心律患者有益。
  • 作者认为达到目标温度的延迟可能是低温控制失败的原因,未来研究应评估30分钟内达到目标温度是否快速改善结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To identify the impact of early hypothermic temperature control (HTC) initiation and achievement on neurologic outcomes after cardiac arrest. Secondary endpoints assessed: 1) overall survival, 2) body temperature at hospital admission, 3) time taken to reach targeted temperature, and 4) adverse events. Subgroup analyses assessed: 1) HTC induction method, 2) presenting rhythms (shockable vs. nonshockable), and 3) timing of HTC initiation (during cardiopulmonary resuscitation [CPR] vs. post-return of spontaneous circulation [ROSC]).

DATA SOURCES: PubMed, Cochrane Library, U.S. National Library of Medicine, MedRxiv, BioRxiv.

STUDY SELECTION: Prospective randomized controlled trials enrolling comatose adult cardiac arrest patients that assessed the efficacy of early cooling (defined by initiation of HTC within 30 min of ROSC) against late cooling.

DATA EXTRACTION: Two reviewers independently conducted study selection, data extraction, and assessment of evidence quality. Full texts were jointly reviewed, with discrepancies resolved by a third reviewer through discussion and consensus.

DATA SYNTHESIS: Of 7269 citations, 11 met the inclusion criteria. Early cooling did not improve neurologic outcomes (risk ratio [RR], 1.01; 95% CI, 0.94-1.14) nor survival (RR, 1.01; 95% CI, 0.92-1.11). Nasal evaporative cooling initiated during resuscitation may benefit patients with shockable rhythms (RR, 1.40; 95% CI, 1.00-1.96), while administering cold fluid during CPR was associated with a higher risk of rearrest. Cooling was initiated in the prehospital phase in ten studies, nine of which failed to achieve target temperature (32-34°C) by hospital admission. The median time to reach target temperature ranged from 38 to 360 minutes.

CONCLUSIONS: Early HTC showed no neurologic nor survival benefit in cardiac arrest survivors. Nasal evaporative cooling during CPR may benefit those with shockable rhythms. Delays in reaching the target temperature may underlie the failure of HTC. Future studies should evaluate whether achieving target temperature, for example, within 30 minutes, rapidly improves outcomes.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Alotaibi KS, Saleem N, Chandos Snow TA, et al. Does Time to Achieve a Targeted Body Temperature Matter for Survivors of Cardiac Arrest? A Systematic Review and Meta-Analysis. Crit Care Med. 2025. PMID: 41217361. doi:10.1097/CCM.0000000000006964

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。